The company's SAGE Direct Platform is a genome-free approach to precision medicine that tests effective cancer treatments on live tissue biopsies of patients. SageMedic collects patients' tumor samples, creates 3D micro-tumors, treats them with approved drugs, and measures the response to identify the most effective treatment. This approach overcomes the limitations of genomic testing by reflecting the heterogeneity and extracellular matrix of the patient's tumor.